Biotech Growth (Ordinary Share) BIOG

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV

878.00

Share Price

799.50

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Biotech Growth (Ordinary Share) Price 64.30%
Biotech Growth (Ordinary Share) NAV 67.08%
FTSE World 58.10%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 808.0 -8.0% 878.00 869.00
21 Jun
104%

Discrete performance % over

Fund / BenchmarkJul '14
Jun '15
Jul '15
Jun '16
Jul '16
Jun '17
Biotech Growth (Ordinary Share) Price68.98-31.1641.25
Biotech Growth (Ordinary Share) NAV66.46-31.2846.06
FTSE World12.142.4537.63

Discrete performance over

Discrete Performance

Top 10 Holdings

Celgene Corporation 12.32%
Biogen Idec Inc., 10.62%
Vertex Pharmaceuticals 9.02%
Regeneron Pharmaceuticals, Inc. 7.41%
Incyte Genomics 6.91%
Alexion Pharmaceuticals, Inc. 6.81%
Illumina, Inc. 4.31%
Amgen Inc 3.91%
DBV Technologies 3.01%
Puma Biotechnology Inc 3.01%

Sectors weighting

Biotechnology 97.90%
General Equity 2.00%
Net Current Assets 0.20%

Regional weighting

North America Region 87.00%
Europe Developed ex-UK 10.00%
UK 2.00%
Asia exc Japan 1.00%
Other Countries 1.00%
Cash/Cash Equivalent 0.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 23 Jun 1997
  • Currency GBX
  • Domicile UK
  • Share Price 799.50
  • Share Type Ordinary Share
  • TIDM BIOG
  • ISIN GB0000385517
  • Shares Issued (M) 56
  • Market Capital (£M) 451.19
  • Gross Assets (£M) 511.34
  • Net Assets (£M) 490.39
  • TER (%) 1.04
  • Last AGM 12 Jul 2016
  • Next AGM 12 Jul 2017
  • Last Annual Report Date 08 Jun 2017
  • Next due Report Date 30 Sep 2017
  • Next due Report Type I/R
  • Objective:

    To achieve capital appreciation through investment in the worldwide biotechnology industry.

  • Management Group(s):

  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • Orbimed Capital LLC
  • Managed by:

  • Geoffrey Hsu Start: 19 May 2005
  • Richard Klemm Start: 19 May 2005
  • Management Contract & Fees:

    Under a new management, administration and company secretarial agreement with Frostrow Capital LLP, Frostrow will receive a periodic fee equal to 0.30% p.a. of the market capitalisation of the Company plus a fixed amount equal to £ 60,000 p.a. The Investment Manager received a fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may by terminated by either giving notice of not less than 12 months'. A performance fee is calculated quarterly by comparing the cumulative performance of the investment portfolio of the Company with the cumulative performance of the benchmark index since 30-Jun-05. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment manager receiving 15% and Manager 1.5% of the outperformance. At each quarterly calculation date any performance fee payable is based on the lower of: (i) the cumulative outperformance of the investment portfolio over the benchmark index as at the quarter end date; and (ii) the cumulative outperformance of the investment portfolio over the benchmark as at the corresponding quarter end date in the previous year. The Contract can be terminated on 12 months' notice.